(Q45007089)

English

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

based on heuristic

inferred from title

fluticasone propionate

1 reference

based on heuristic

inferred from title

author name string

Richard D O'Connor

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Harold Nelson

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Rohit Borker

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Amanda Emmett

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Priti Jhingran

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Kathleen Rickard

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Paul Dorinsky

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

815-825

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

https://scigraph.springernature.com/pub.10.2165/00019053-200422120-00004

0 references

The health economics of asthma and rhinitis. I. Assessing the economic impact

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Assessing the appropriateness of combining economic data from multinational clinical trials

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Reimbursements. Inching closer to actual charges

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cost of asthma in the emergency department and hospital

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-200422120-00004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Dimensions Publication ID

0 references

release_s6dgs7vwefbvzmfgb7hr4p5qea

1 reference

https://api.fatcat.wiki/v0/release/s6dgs7vwefbvzmfgb7hr4p5qea

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45007089&oldid=2062266430"